araag2/HINT huggingface dataset:
Clinical trial NCT00366080 (phase 2, status: terminated)
Conditions: narcolepsy
ICD codes: G47.411, G47.419, G47.421, G47.429
Drugs: gsk189254
SMILES: CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1
Reason stopped: 
    study was terminated based on the interim results of a futility test.
  
Eligibility criteria:

        Inclusion criteria:

          -  Narcolepsy patients

          -  Body mass index between 18 - 32 kg/m2

          -  Females may be of child bearing or non-child bearing potential.

          -  Agreement to refrain from driving or operating heavy machinery for the duration of the
             study.

          -  Must be able to withdraw from medication for the treatment of daytime sleepiness and
             must not be living on their own.

        Exclusion criteria:

          -  History or presence of major psychiatric disorder or depression.

          -  History of significant head trauma in the previous 12 months.

          -  Participation in a clinical trial in the previous 3 months.

          -  Patient has significant and recent (within 1 year) history of drug or alcohol abuse.

          -  Patient is pregnant or breast-feeding.
Clinical trial NCT01385592 (phase 2, status: completed)
Conditions: dyskinesias, parkinson disease, movement disorders, parkinsonian disorders
ICD codes: G20, G47.61, G25.70, G25.9, H51.9, F98.4, G25.79, G25.89
Drugs: afq056, placebo
SMILES: COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1=CC(C)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing
             dyskinesias for at least three months

          -  Outpatients who are on a stable anti-parkinsonian treatment regimen for at least four
             weeks

        Exclusion Criteria:

          -  Surgical treatment for PD

          -  Cancer within the past 5 years (other than localized skin cancer and prostate cancer
             that has been effectively treated)

          -  Advanced, severe or unstable disease (other than PD) or evidence of dementia that may
             interfere with the study outcome evaluations

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00003663 (phase 2, status: withdrawn)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    no patient accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven stage III or IV, recurrent or refractory,
        indolent B cell non-Hodgkin's lymphoma of the following types: Working Group Formulation A
        (small cell lymphocytic) Working Group Formulation B, C, and D (follicular) Must have
        relapsed after prior chemotherapy At least 1 lymph node or visceral lesion at least 2 cm in
        diameter

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Lymphocyte count less than 5,000/mm3 Hepatic: Not specified Renal:
        Not specified Other: Not pregnant or nursing Fertile patients must use effective
        contraception No active infection HIV negative No hepatitis B or C No concurrent life
        threatening condition

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibody therapy for
        lymphoma (e.g., rituximab) Chemotherapy: See Disease Characteristics Endocrine therapy: No
        other concurrent corticosteroids and/or epinephrine (unless anaphylactic shock)
        Radiotherapy: Not specified Surgery: Not specified
Clinical trial NCT00686036 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: vandetanib, placebo
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of prostate cancer

          -  Prostate specific antigen (PSA) greater than or equal to 5 ng/mL

          -  Recent completion of first hormone treatment [intermittent androgen deprivation with a
             Luteinising hormone releasing hormone (LHRH) analogue]

          -  Screening PSA ≤1.0 ng/mL (within 6 weeks prior to study Day1)

        Exclusion Criteria:

          -  Bone or soft tissue metastases

          -  Significant cardiovascular disease including hypertension not controlled by medical
             therapy or history of irregular heart beats or recent heart attack
Clinical trial NCT00498628 (phase 2, status: completed)
Conditions: alcoholism, alcohol abuse
ICD codes: Z63.72, F10.10, F10.14, F10.180, F10.181, F10.182, F10.188, F10.19
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Between the ages of 18 and 65 years old

          -  DSM-IV diagnosis of current alcohol dependence as supported by SCID Module E

          -  Report "very heavy" drinking (10 or more drinks per drinking day for men or 8 or more
             drinks per drinking day for women) at least 40% of the days during the interval from
             day 31 to 90 prior to the initial screening visit (i.e. a total of 24 days of this
             60-day period), with at least one day of "very heavy" drinking occurring within the
             last 2 weeks before screening

          -  Seeking treatment for alcohol dependence and desire reduction or cessation of drinking

          -  Able to verbalize understanding of the consent form, able to provide written informed
             consent, and verbalize willingness to complete study procedures

          -  Females of child bearing potential must agree to use of at least one approved method
             of birth control, or must be surgically sterile or postmenopausal

          -  Able to take oral medication, willing to adhere to the medication regimen, and willing
             to return for regular visits

          -  Able to understand written and oral instructions in English and to complete the
             questionnaires required by the protocol

          -  Can complete all psychological assessments required at screening and baseline

          -  Able to provide evidence of stable residence in the last 2 months prior to
             randomization, have reasonable transportation arrangements to study site, and have no
             plans to move within the next 3 months or unresolved legal problems; must provide
             contact information of family member, spouse, or significant other who can contact
             subject in case of missed appointment

          -  Breath alcohol concentration (BAC) equal to 0.00 when s/he signed the informed consent
             document

          -  Must have an absolute neutrophil count of 1.5 x 109/L or greater.

        Exclusion Criteria:

        Please contact site for additional information.
Clinical trial NCT01057927 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: oc000459, placebo
SMILES: CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria At Screening:

          -  Male or female asthmatics, any racial group. Females of childbearing potential must
             practise two forms of contraception

          -  Non smokers

          -  Mild to moderate asthmatics according to GINA guidelines for at least 12 months.

          -  History of asthma symptoms increasing in response to external allergens.

          -  Testing positive on skin prick test to an allergen associated with the subject's
             asthma

        Exclusion Criteria:

          -  Use of inhaled or local corticosteroids in the period from 28 days prior to screening.

          -  Receipt of prescribed or over the counter medication within 14 days of the first study
             day.
Clinical trial NCT00403988 (phase 2, status: terminated)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: oxaliplatin, vinorelbine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    the results of a same study design have shown low response with important side effects.
    accordingly & ethicly, the study has been stopped.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic, histologically or cytologically proven breast cancer.

          -  At least one bi-dimensionally measurable lesion.

          -  Previous treatment with chemotherapy as first line for metastatic disease is mandatory
             especially with anthracyclines +/- the Taxanes.

          -  Treatment as adjuvant is allowed.

          -  World Health Organization-ECOG performance status 0-2.

          -  Adequate renal function (Creatinine <= 1.4 or Creatinine clearance >= 30 ml/min)

          -  Adequate hepatic function (Liver Function Tests not more than 3 times the normal
             values)

          -  Adequate bone marrow reserve is required (Neutrophils (PMN) >= 2000/mm2 and Platelets
             >= 100,000/mm2)

          -  Patient who will receive Herceptin should have an over-expression of HER2-neu.

        Exclusion Criteria:

          -  Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria
             grade more than one).

          -  Pregnant or breast-feeding.

          -  History of prior malignancies (with the exception of excised cervical
             carcinoma-in-situ or non-melanoma cell skin carcinoma).

          -  Receiving or had received, any treatment with experimental drugs.

          -  Had known brain or leptomeningeal involvement.

          -  Had a serious medical condition like congestive heart failure or an Ejection Fraction
             ≥ 40 %.

          -  The presence of bone as a sole site of metastasis.

          -  Radiation therapy to all areas of measurable disease less than four weeks before
             treatment.

          -  Creatinine two times above the normal range

          -  Hypercalcemia

          -  Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion
             - Ascites - Pericardial effusion.

          -  Concomitant steroid intake for > 4 weeks

          -  Bilirubin two times above the normal range

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00477087 (phase 2, status: terminated)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: mitoxantrone, gm-csf
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Age ≥ 18 years

          -  Histologically-confirmed adenocarcinoma of the prostate

          -  Hormone-refractory prostate cancer

          -  Failed 1st-line docetaxel-containing regimen

          -  No prior immunotherapy including:

               -  Vaccines

               -  GM-CSF

          -  Minimum prostate-specific antigen (PSA) > 5 mg/dL and rising according to the PSA
             Consensus Criteria

          -  Karnofsky Performance Status (KPS) > 60%

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status < 3

          -  Life expectancy > 6 months

        Exclusion Criteria:

          -  Concomitant hormonal therapy other than luteinizing hormone-releasing hormone (LHRH)
             agonist

          -  Use of herbal products known to decrease PSA levels

          -  Use of supplements or complementary medicines, except for:

               -  Conventional multivitamin supplements

               -  Selenium

               -  Lycopene

               -  Soy supplements

               -  Vitamin E

          -  Initiation of bisphosphonates within one month prior to enrollment or throughout the
             study

          -  Any prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to
             enrollment

          -  Major surgery or radiation therapy completed < 4 weeks prior to enrollment

          -  Any concomitant second malignancy other than non-melanoma skin cancer

          -  Any concomitant serious infection

          -  Any nonmalignant medical illness

          -  Absolute neutrophil count (ANC) < 1,500/µL

          -  Platelet count < 100,000 µL

          -  Hemoglobin < 8 mg/dL

          -  Total bilirubin greater than 1.5 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN if no
             demonstrable liver metastases, or greater than 5.0 x ULN in presence of liver
             metastases

          -  Ejection fraction < 50% as measured by echocardiogram (ECHO) or multigated acquisition
             (MUGA) scan

          -  Noncompliance with study procedures
Clinical trial NCT00735241 (phase 2/phase 3, status: withdrawn)
Conditions: colorectal carcinoma, liver metastases
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: folfox6 cycles 1-3, folfox6 cycles 4 onwards, bevacizumab cycles 3 onwards
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    withdrawn by the study sponsor.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the colon or rectum.

          -  Unequivocal and measurable CT evidence of liver metastases which are not treatable by
             surgical resection or local ablation with curative intent.

          -  ECOG performance status 0 - 1.

          -  Adequate hematological, renal and hepatic function.

        Exclusion Criteria:

          -  Evidence of ascites, cirrhosis, portal hypertension, main portal vein tumor
             involvement or thrombosis as determined by clinical or radiologic assessment.

          -  Any extra-hepatic metastases other than metastases in the lungs and/or bones and/or
             abdominal or hilar lymph nodes. Central nervous system (CNS) metastases are not
             allowed.

          -  Previous radiotherapy delivered to the upper abdomen.

          -  Peripheral neuropathy > grade 1 (NCI-CTCv3).
Clinical trial NCT00642902 (phase 2, status: terminated)
Conditions: relapsing multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: atacicept, atacicept, atacicept, placebo matched to atacicept
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor voluntarily decided to terminate trial due to increased ms disease activity in
    atacicept arms as compared to placebo during a routine idmc review.
  
Eligibility criteria:

        Inclusion Criteria:

        - Diagnosis of RMS (as per McDonald criteria, 2005) Other protocol-defined inclusion
        criteria could apply.

        Exclusion Criteria:

          -  Have primary progressive multiple sclerosis (MS)

          -  Have secondary progressive MS without superimposed relapses

          -  Relevant cardiac, hepatic and renal diseases as specified in the protocol

          -  Pretreatment with immunosuppressants and immunomodulating drugs as specified in the
             protocol

          -  Clinical significant abnormalities in blood cell counts and immunoglobulin levels as
             specified in the protocol

          -  Clinical significant acute or chronic infections as specified in the protocol Other
             protocol-defined exclusion criteria could apply.
Clinical trial NCT00236678 (phase 2, status: terminated)
Conditions: anemia, rheumatoid arthritis
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    this study was terminated due to slow enrollment, despite protocol amendments to change the
    entrance criteria.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have rheumatoid arthritis with chronic anemia. Patients must have signed
             an informed consent

          -  women must be postmenopausal for at least one year, surgically sterile, or practicing
             an effective method of birth control, or have a negative serum pregnancy test

          -  women must not be breast feeding during this study period.

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  elective surgery, including joint replacement, anticipated to require transfusion
             during the extension study period

          -  thromboembolic event during the double-blind study including acute myocardial
             infarction, cerebrovascular accident and/or transient ischemic attack

          -  deep vein thrombosis and/or pulmonary embolism

          -  uncontrolled psychiatric disease

          -  planning to be enrolled in any other clinical trial during the course of this study
Clinical trial NCT01804400 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: qaw039, montelukast, placebo
SMILES: CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(C=C1C(F)(F)F)S(C)(=O)=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18-65 years inclusive, with a clinical history of intermittent
             allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each
             of the last two grass pollen allergy seasons.

          -  A positive skin prick test at Visit 1 to dactylis glomerata with a wheal diameter
             equal to or greater than 3 mm and a negative control with a wheal diameter of zero. A
             positive skin prick test within 12 months prior to Visit 1 is also acceptable.

          -  FEV1 measured by spirometry must be ≥80% of their predicted value at screening. If the
             patient does not achieve ≥80% of their predicted value this may be repeated prior to
             the EEC challenge at visit 2.

          -  TNSS score ≥6 on at least one assessment during the 2h EEC challenge at Screening.

        Exclusion Criteria:

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer; or longer if required by local
             regulations, and for any other limitation of participation in an investigational trial
             based on local regulations.

          -  Pregnant or nursing (lactating) women,

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using effective methods of contraception during
             dosing of study treatment.
Clinical trial NCT01545427 (phase 2, status: terminated)
Conditions: scleroderma
ICD codes: L94.1, L94.0
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    frequent adverse events occurred early in treatment with poor tolerability.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be able to give informed consent.

          -  Subjects must meet preliminary criteria for scleroderma.

          -  Subjects must have diffuse skin involvement.

          -  Disease must appear to be active as measured by worsening skin score and/or increased
             ESR.

          -  Serum SGOT < 1.5 times upper limit of normal.

          -  Bilirubin < 1.5 times upper limit of normal.

          -  AST/ALT < 2.5 times upper limit of normal

        Exclusion Criteria:

          -  Any past exposure to Gleevec.

          -  Women of child bearing potential must be practicing an acceptable form of
             contraception (OCP, depo-provera, IUD, condoms with spermicidal or sterilization of
             subject or partner).

          -  Women who are breastfeeding.

          -  Men whose partners could conceive must be practicing acceptable contraception (see
             above).

          -  Certain abnormal labs including: Neutrophil count <1.5X109/L, platelets < 50X109/L.

          -  Serious comorbidity that may impair the ability to complete the study (such as severe
             heart disease, severe pulmonary hypertension) and other comorbidities.

          -  Prednisone at doses of >10mg/od.

          -  Other potential disease modifying drugs such as cyclophosphamide, mycophenylate and
             methotrexate.

          -  Serious liver disease.

          -  Creatinine >200.

          -  Excluded: Ketoconazole and fluconazole, cyclosporine, rifampin, phenytoin nefazodone,
             pimozide, propafenone, quinidine, sibutramine and sildenafil where drug interactions
             could occur.

          -  Subjects taking endothelin receptor blockers such as bosentan and sitaxsentan.

          -  Alcohol consumption of > 3 drinks per week.
Clinical trial NCT01144624 (phase 2, status: completed)
Conditions: severe sepsis, septic shock
ICD codes: R65.20, R65.21, T81.12XS, R65.20, R65.21, T81.12XA, T81.12XD
Drugs: azd9773, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese adults with a first episode of sepsis during this hospitalisation and
             objective evidence of infection that requires parenteral antibiotics.

          -  At least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction (must include
             either fever OR elevated white blood cells [WBC])

          -  Cardiovascular or respiratory dysfunction.

        Exclusion Criteria:

          -  Immunocompromising comorbidities or concomitant medications:

               1. Advanced human immunodeficiency virus (HIV) infection (CD4 ≤50/mm3).

               2. Haemopoietic or lymphoreticular malignancies not in remission.

               3. Receiving radiation therapy or chemotherapy.

               4. Any organ or bone marrow transplant within the past 24 weeks.

               5. Absolute neutrophil count <500 per μL.

               6. High dose steroids or other immunocompromising drugs.

          -  Concomitant diseases:

               1. Deep-seated fungal infection or active tuberculosis.

               2. Severe chronic liver disease associated with portal hypertension, cirrhosis,
                  chronic ascites or Child-Pugh class C.

               3. History of chronic hypercarbia, respiratory failure in past 6 months or use of
                  home oxygen in the setting of severe chronic respiratory disease.

               4. Neuromuscular disorders that impact breathing/spontaneous ventilation.

               5. Quadriplegia.

               6. Cardiac arrest in the past 30 days.

               7. New York Heart Association functional Class III or IV due to heart failure or any
                  disorder.

               8. Burns over > 30% of body surface area in the past 5 days.

          -  Medication and allergy disqualifications.

               1. Treatment with anti-TNF agents within the last 8 weeks.

               2. Previously received ovine derived products (CroFab™, DigiFab™).

               3. Sheep product allergy or allergy to papain, chymopapain.